Search
- Apr 11
Wedbush's Robert Driscoll joins BiotechTV for Analyst Thursdays
He discusses Vertex's acquisition of Alpine Immune Science, Bloomberg's reporting on Janux, and more.
- Apr 10
The CEO of Madrigal on the launch of Rezdiffra for NASH liver disease
Bill Sibold describes how Madrigal has prepared for the launch and illustrates how the medicine is meant to impact disease progression.
- Apr 9
AACR24: Having entered the clinic last night, Nested's CEO discusses the preclinical profile of a brain-penetrant, pan-RAF/MEK molecular glue
Darrin Miles describes how this molecular glue therapy has been designed to bind to MEK and all isoforms of MEK and RAF in combination.
- Apr 9
AACR24: EpicentRx’s phase 2a using TGF-β trap to overcome checkpoint resistance
EpicentRx CEO Tony Reid and MD Andersen investigator Anthony Conley describe TGF-β data presented at AACR.
- Apr 9
Daphne Zohar on becoming the CEO of Seaport Therapeutics and today's $100M series A
She describes working with Steven Paul again, the Glyph technology that is the backbone of Seaport's platform, and more.
- Apr 9
TCGX's Chen Yu describes the benefits of being able to focus on public and privates during different stages of the biotech cycle
Dr. Yu describes how TCGX's structure and nimbleness has led to investments in number companies that have been acquired over the last year.